Pfizer makes moves to offload Hospira's pumps and devices business

Pfizer headquarters

Pfizer ($PFE) has begun taking offers on Hospira’s pumps and devices business, after considering offloading it for some time. A sale would free Pfizer of an acquisition that falls outside the scope of its traditional drug business.

Med tech companies Smiths Group and Fresenius put in bids for the unit, which Pfizer picked up last year through its $15 billion deal for Hospira. Private equity firm Pamplona Capital made a second-round bid for the business, Bloomberg reports, although final bids for the unit aren’t due until the end of May.

Pfizer has said that it could reap about $2 billion from a sale of Hospira’s devices business. Representatives from Pfizer, Germany’s Fresenius and London-based Smiths Group declined to comment to the news outlet.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Pfizer snatched up Hospira in order to get its hands on the company’s biosimilars and generic injectables. Hospira’s pumps and devices unit doesn’t fit in with the rest of Pfizer’s established products business, and selling the business would create a more pure-play drugs unit that’s ripe for a sale, IPO or spinoff.

More changes could also be on the horizon for Pfizer after its $160 billion deal with Allergan ($AGN) fell through last month. The company is going to decide by the end of this year whether it should break into two separate businesses, its original timeline for the breakup, Pfizer CEO Ian Read said at the time.

And meanwhile, the drug giant will continue to scout out deals and explore "other shareholder friendly capital allocation opportunities," he said in a statement.

- read the Bloomberg story
- here’s the Telegraph article

Related Articles:
Hospira's floundering pumps business nears the chopping block: Bloomberg
For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg
Pfizer grabs Hospira's biosims, generic injectables in $15B takeover
Pfizer's $160B megadeal for Allergan collapses under new tax rules
With Pfizer set to buy Hospira, what's in the future for CEO F. Michael Ball?

Read more on

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.